Table 3.
Site of GI and hepatic involvement and QOL and HAP scores (“---” indicates variables that were lack of significance and dropped from multivariate models)
| SF36 PCS | SF36 MCS | FACT G | FACT TOI | FACT BMT | HAP MAS | HAP AAS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Estimate | p-value | Estimate | p-value | Estimate | p-value | Estimate | p-value | Estimate | p-value | Estimate | p-value | Estimate | p-value | |
| Esophagus | --- | --- | --- | --- | −1.68 | 0.04 | --- | --- | --- | --- | --- | --- | --- | --- |
| Upper GI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lower GI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| GI 0-3 | −1.54 | 0.002 | −2.86 | <0.001 | −3.81 | <0.001 | −4.29 | <0.001 | −5.70 | <0.001 | −2.19 | 0.001 | −2.10 | 0.004 |
| Bili | --- | --- | −3.44 | 0.001 | −2.66 | 0.04 | −3.24 | 0.009 | −3.76 | 0.03 | −3.78 | 0.002 | −4.36 | 0.003 |
| ALP | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | −2.29 | 0.002 |
| ALT | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Liver 0-3 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
*
Data represent results from multivariate analyses using all available visit data. Covariates adjusted included: patient age at transplant (<50 vs. higher), patient gender, patient education level, month from HCT to cohort enrollment (<12 months vs. higher), donor-patient gender combination (female into male vs. other), transplant type (myeloablative vs. not), source, Karnofsky performance status at onset (<80, 80+, missing), case (incident, prevalent), platelet count at enrollment (<100K vs. higher), site (FHCRC vs. other)